Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.49 |
| ▸ | LPL | P06858 | 9/20 | 0.49 |
| ▸ | P4HB | P07237 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | F11 | P03951 | 3/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760918 | 0.84 | LPL (0.53) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL26831135 | 0.80 | LPL (0.53) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL16595477 | 0.79 | LIPG (0.53) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL476844 | 0.79 | LPL (0.52) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL105188 | 0.79 | LIPG (0.56) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL26773260 | 0.78 | P4HB (0.62) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL15481263 | 0.78 | P4HB (0.48) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL476916 | 0.77 | F11 (0.53) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL13600363 | 0.77 | LIPG (0.50) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL29135789 | 0.77 | CA1 (0.50) | LIPGLPLP4HBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193228-B2 | Substituted imidazole as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| EP-2091937-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008051406-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | BRS3, INSR, INSRR | LIPG 2316/4885LPL 2150/4885P4HB 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.